- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07712198
Al Prediction of Sarcopenia Risk in Neurocritical ICU Patients
Artificial Intelligence-Based Prediction of Sarcopenia Risk in Intensive Care Unit Patients With Intracranial Pathology
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This study is designed as a prospective observational study. Patients admitted to the Level III Intensive Care Units of Trabzon University Faculty of Medicine, Kanuni Training and Research Hospital, Kaşüstü Campus, due to intracranial pathologies between January 1, 2026, and June 30, 2026, will be included. Approximately 100-150 patients are planned to be evaluated.
Demographic data of the enrolled patients will be recorded, and the modified Nutrition Risk in Critically Ill (mNUTRIC) score will be calculated on the first day of intensive care unit admission. Rectus femoris muscle thickness will be evaluated by ultrasonography on Day 0 and Day 7 of ICU admission. All ultrasonographic measurements will be performed using the same ultrasound device and by the same investigator according to a standardized protocol. During the measurements, the patient will be positioned supine, the knee will be kept in extension, and the muscle will be evaluated in a relaxed position. Three repeated measurements will be obtained at each assessment, and the mean value will be recorded.
As part of the laboratory assessment, prealbumin levels will be measured on Days 0, 3, and 7. Biochemical parameters evaluated during routine clinical follow-up will be recorded from the hospital information system.
No intervention, additional procedure, or treatment modification will be performed as part of this study. All data will consist of observational data obtained during routine clinical follow-up. Data collection will be conducted by a resident physician from the Department of Anesthesiology and Reanimation with experience in intensive care.
The collected clinical, laboratory, and ultrasonographic data will be provided to different artificial intelligence models, and their accuracy and performance in predicting sarcopenia development on Day 7 will be evaluated. The primary objective of the study is to assess the predictive performance of artificial intelligence models, including ChatGPT, Gemini, and Claude, for Day 7 sarcopenia development in intensive care patients with intracranial pathologies. Secondary objectives include comparing artificial intelligence predictions with clinical assessments, comparing predictive performance among different artificial intelligence models, and evaluating the potential usability of artificial intelligence models as clinical decision-support tools in intensive care practice.
All data will be de-identified before analysis, and patient confidentiality will be maintained. Study data will be stored in a secure digital environment accessible only to the research team.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: KİRAZ TEKİN GÜNAYDIN, MD
- Telefoonnummer: +905369549350
- E-mail: kiraztekin.16@gmail.com
Studie Locaties
-
-
-
Trabzon, Turkije (Türkiye)
- Werving
- Trabzon University Faculty of Medicine, Kanuni Training and Research Hospital, Trabzon, 61080
-
Contact:
- Recep Erin, MD
- Telefoonnummer: +905304699135
- E-mail: erinrecep@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Age between 18 and 65 years
- Admission to the intensive care unit due to intracranial pathology (intracerebral hemorrhage, epidural hemorrhage, subdural hemorrhage, subarachnoid hemorrhage, intracranial tumors, or ischemic stroke)
- Informed consent obtained from the patient or legally authorized representative
Exclusion Criteria:
- Age <18 years or >65 years
- Failure to achieve nutritional targets according to ESPEN guidelines
- Palliative care or home care patients
- Morbid obesity (BMI ≥40 kg/m²)
- History of neuromuscular disease
- Lower extremity amputation
- History of trauma affecting the thigh region
- Pregnancy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Intracranial Pathology ICU Patients
Adult patients admitted to the intensive care unit with intracranial pathologies, including intracerebral hemorrhage, subarachnoid hemorrhage, subdural hematoma, epidural hematoma, intracranial tumors, and ischemic stroke.
Participants will be prospectively observed.
Rectus femoris muscle thickness will be measured by ultrasonography on days 0 and 7, and prealbumin levels will be assessed on days 0, 3, and 7.
No experimental intervention or treatment modification will be performed.
|
Prospective observational assessment including rectus femoris ultrasonography, prealbumin measurements, mNUTRIC scoring, and collection of routine clinical data.
No experimental intervention or treatment modification will be performed.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Accuracy of Artificial Intelligence Models in Predicting Day-7 Sarcopenia
Tijdsspanne: 7 Days
|
Evaluation of the predictive performance of ChatGPT, Gemini, and Claude models for day-7 sarcopenia in ICU patients with intracranial pathology using rectus femoris muscle thickness, prealbumin levels, and clinical data.
|
7 Days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Comparison of Predictive Performance Among AI Models
Tijdsspanne: 7 Days
|
Comparison of prediction accuracy among ChatGPT, Gemini, and Claude models for day-7 sarcopenia.
|
7 Days
|
|
Agreement Between AI Predictions and Clinical Assessment
Tijdsspanne: 7 Days
|
Evaluation of concordance between artificial intelligence model predictions and clinically determined sarcopenia status.
|
7 Days
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Algemene publicaties
- Phongpreecha T, Ghanem M, Reiss JD, Oskotsky TT, Mataraso SJ, De Francesco D, Reincke SM, Espinosa C, Chung P, Ng T, Costello JM, Sequoia JA, Razdan S, Xie F, Berson E, Kim Y, Seong D, Szeto MY, Myers F, Gu H, Feister J, Verscaj CP, Rose LA, Sin LWY, Oskotsky B, Roger J, Shu CH, Shome S, Yang LK, Tan Y, Levitte S, Wong RJ, Gaudilliere B, Angst MS, Montine TJ, Kerner JA, Keller RL, Shaw GM, Sylvester KG, Fuerch J, Chock V, Gaskari S, Stevenson DK, Sirota M, Prince LS, Aghaeepour N. AI-guided precision parenteral nutrition for neonatal intensive care units. Nat Med. 2025 Jun;31(6):1882-1894. doi: 10.1038/s41591-025-03601-1. Epub 2025 Mar 25.
- Lopez-Gomez JJ, Sanchez-Lite I, Fernandez-Velasco P, Izaola-Jauregui O, Cebria A, Perez-Lopez P, Gonzalez-Gutierrez J, Estevez-Asensio L, Primo-Martin D, Gomez-Hoyos E, Jorge-Godoy E, De Luis-Roman DA. Artificial intelligence-assisted rectus femoris ultrasound vs. L3 computed tomography for sarcopenia assessment in oncology patients: establishing diagnostic cut-offs for muscle mass and quality. Front Nutr. 2025 Sep 25;12:1678989. doi: 10.3389/fnut.2025.1678989. eCollection 2025.
- Choi YH, Kim DH, Jeon ET, Lee HJ, Park TY, Yoon SH, Jin KN, Lee HW. Cluster analysis of thoracic muscle mass using artificial intelligence in severe pneumonia. Sci Rep. 2024 Jul 23;14(1):16912. doi: 10.1038/s41598-024-67625-2.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Neuromusculaire manifestaties
- Wonden en verwondingen
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Pathologische aandoeningen, anatomisch
- Bloeding
- Neoplasmata van het zenuwstelsel
- Craniocerebraal trauma
- Trauma, zenuwstelsel
- Neoplasmata van het centrale zenuwstelsel
- Spieratrofie
- Atrofie
- Intracraniële bloedingen
- Hartinfarct
- Intracraniële bloeding, traumatisch
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Hematoom
- Ischemische beroerte
- Hersenneoplasmata
- Sarcopenie
- Hersenbloeding
- Hematoom, subduraal
- Subarachnoïdale bloeding
- Hematoom, epiduraal, ruggenmerg
Andere studie-ID-nummers
- 10496660-2026-25030
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .